

Trials and Trial Regimen Updates

Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAlysts@scri.com.

Study Number	New Build Completed			Notes for New Build
23084	x			USOR 23084 Cohort 1 Arm 1 BT8009 D1,8,15 + Pembrolizumab Q21D USOR 23084 Cohort 1 Arm 2 BT8009 D1,8 + Pembrolizumab Q21D USOR 23084 Cohort 1 Arm 3 Gemcitabine D1,8 + Carboplatin Q21D USOR 23084 Cohort 1 Arm 3 Gemcitabine D1,8 + Cisplatin Q21D USOR 23084 Cohort 1 Arm 3 Maintenance Avelumab D1,15 Q28D USOR 23084 Cohort 2 Arm 1 BT8009 D1,8,15 Q21D USOR 23084 Cohort 2 Arm 2 BT8009 D1,8 Q21D USOR 23084 Cohort 2 Arm 3 BT8009 + Pembrolizumab Q21D

Study Number	New Build Completed		
			Notes for New Build
23340	X		USOR 23340 Cohort 1 Livmoniplimab + Budigalimab + Pemetrexed + Carboplatin Q21D USOR 23340 Cohort 1 Livmoniplimab + Budigalimab + Pemetrexed + Cisplatin Q21D USOR 23340 Cohort 1 Maintenance Livmoniplimab + Budigalimab + Pemetrexed Q21D USOR 23340 Cohort 2 Livmoniplimab + Budigalimab + Pemetrexed + Carboplatin Q21D USOR 23340 Cohort 2 Livmoniplimab + Budigalimab + Pemetrexed + Cisplatin Q21D USOR 23340 Cohort 2 Maintenance Livmoniplimab + Budigalimab + Pemetrexed Q21D USOR 23340 Cohort 3 Budigalimab + Pemetrexed + Carboplatin Q21D USOR 23340 Cohort 3 Budigalimab + Pemetrexed + Cisplatin Q21D USOR 23340 Cohort 3 Maintenance Budigalimab + Pemetrexed Q21D USOR 23340 Maintenance Pembrolizumab + Pemetrexed Q21D USOR 23340 Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 23340 Pembrolizumab + Pemetrexed + Cisplatin Q21D
22095	X		USOR 22095 DSP-5336 Q28D USOR 22095 Part 1 DSP-5336 + Gilteritinib Q28D USOR 22095 Part 1 DSP-5336 + Venetoclax + Azacitidine D1-7 Q28D

Study Number	New Build Completed		
	Notes for New Build		
23284	x		USOR 23284 ABBV-383 Q28D USOR 23284 Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D USOR 23284 Carfilzomib D1,8,15 + Dexamethasone Q28D USOR 23284 Elotuzumab D1,8,15,22 fb D1 + Pomalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D USOR 23284 Selinexor D1,8,15,22,29 + Bortezomib D1,8,15,22 + Dexamethasone Q35D
23283	x		USOR 23283 Rilvegostomig or Placebo + Capecitabine Q21D USOR 23283 Rilvegostomig or Placebo + Gemcitabine D1,8 + Cisplatin D1,8 Q21D
24049	x		USOR 24049 HMPL-523 Part 1 Dose Escalation
20345	x		USOR 20345 Selinexor or Placebo + Ruxolitinib
21271			Administrative Amendment
22298			Administrative Amendment

Study Number	Updated Reference Information		
	Updated Drug Service Order Information		
	Updated Regimen Instructions		
	Other Changes		
22220			Administrative Amendment
22187			Updated Pharmacy Manual Administrative Amendment
23195			Updated Pharmacy Manual Administrative Amendment

Study Number	Updated Reference Information		
	Updated Drug Service Order Information		
	Updated Regimen Instructions		
	Other Changes		
23009			Administrative Amendment
23261			Updated Pharmacy Manual Administrative Amendment
23244			Updated Pharmacy Manual Administrative Amendment
21457			Administrative Amendment
22232			Administrative Amendment
23016			Administrative Amendment
21533			Administrative Amendment
22022			Administrative Amendment
23203			Administrative Amendment